MEN1 and gallstones: Additionally, the safety profile (for octreotide as well as for lanreotide) appeared similar to that reported for cases of pNENs not associated with MEN1: 78.2% of patients did not report SSA-related side effects and only a minority of subjects showed low-grade and manageable toxicities (with gallstones being the main side effect) [30].